Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics. by Guo, Ju-Tao & Guo, Haitao
Metabolism and function of hepatitis B virus cccDNA: 
Implications for the development of cccDNA-targeting antiviral 
therapeutics
Ju-Tao Guo1,* and Haitao Guo2,*
1Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania, USA.
2Department of Microbiology and Immunology, Indiana University School of Medicine, 635 
Barnhill Drive, Indianapolis, IN 46202, USA.
Abstract
Persistent hepatitis B virus (HBV) infection relies on the stable maintenance and proper 
functioning of a nuclear episomal form of the viral genome called covalently closed circular (ccc) 
DNA. One of the major reasons for the failure of currently available antiviral therapeutics to 
achieve a cure of chronic HBV infection is their inability to eradicate or inactivate cccDNA. In 
this review article, we summarize our current understanding of cccDNA metabolism in 
hepatocytes and the modulation of cccDNA by host pathophysiological and immunological cues. 
Perspectives on the future investigation of cccDNA biology, as well as strategies and progress in 
therapeutic elimination and/or transcriptional silencing of cccDNA through rational design and 
phenotypic screenings, are also discussed. This article forms part of a symposium in Antiviral 
Research on “An unfinished story: from the discovery of the Australia antigen to the development 
of new curative therapies for hepatitis B.”
1. Introduction
Despite the availability of effective vaccines for more than three decades, an estimated 240 
million individuals are still chronically infected with hepatitis B virus (HBV), and HBV-
related diseases account for 600,000 deaths per year (Ott et al., 2012). Seven drugs are 
currently approved for the treatment of chronic hepatitis B, which include two formulations 
of alpha-interferon (standard and pegylated) that modulate the host antiviral immune 
responses and five nucleos(t)ide analogues (lamivudine, adefovir, entecavir, telbivudine, and 
tenofovir) that inhibit HBV DNA polymerase (Keeffe et al., 2008; Zoulim and Locarnini, 
2009). Pegylated IFN-α therapy is effective in achieving a sustained virological response -- 
defined as hepatitis e antigen (HBeAg) seroconversion and/or reduction in HBV DNA levels 
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to below 20,000 copies/mL at 6 months after the completion of a 48-week course of therapy 
-- in only 30% of HBeAg-positive and 40% of HBeAg-negative cases (Janssen et al., 2005; 
Lau et al., 2005; Perrillo, 2009). Nucleos(t)ide analogues profoundly reduce the viral load in 
vast majority of treated patients, which is associated with significant improvement of liver 
function and reduced incidence of liver failure and hepatocellular carcinoma (Liaw, 2013). 
However, even prolonged treatment rarely cures chronic HBV infection, and virological 
relapse is common after treatment cessation (Zoulim and Locarnini, 2009).
Accumulating evidence suggests that the inability to eliminate the nuclear episomal form of 
the viral genome, the covalently closed circular (ccc) DNA, by currently available 
therapeutics, is one of the critical reasons for failure to achieve a functional cure (Bowden et 
al., 2015; Sung et al., 2005; Werle-Lapostolle et al., 2004; Wursthorn et al., 2006). 
Unraveling the molecular mechanism of cccDNA metabolism and regulation by host 
antiviral immune responses could facilitate the discovery and development of antiviral 
agents and immunotherapeutics that would effectively induce more durable suppression of 
HBV replication following the cessation of treatment and ideally achieve a functional cure 
(Block et al., 2013).
2. Molecular pathway of cccDNA biosynthesis
HBV is a small DNA virus with a relaxed circular (rc) partially double-stranded 3.2kb 
genome (Summers et al., 1975). Unique structural properties of the genome include the 
asymmetry in length of the two strands of DNA and the covalent linkage of the viral DNA 
polymerase protein to the 5’-terminus of minus-strand DNA (Bartenschlager and Schaller, 
1988; Gerlich and Robinson, 1980; Molnar-Kimber et al., 1983). These structural features 
provided early clues for uncovering HBV DNA replication via a mechanism other than 
semiconservative replication (Mason et al., 1982), i.e., polymerase protein-primed reverse 
transcription of an RNA intermediate called pregenomic (pg) RNA (Summers and Mason, 
1982; Wang and Seeger, 1992). However, distinct from retroviruses, the integration of HBV 
genomic DNA into host cellular chromosomes is not an obligatory step in the life cycle of 
HBV (Seeger and Mason, 2015). Instead, upon entry into the cytoplasm of hepatocyte, 
rcDNA in the nucleocapsid is transported into the nucleus and converted into the episomal 
cccDNA, which serves as the template for the transcription of viral mRNAs (Summers and 
Mason, 1982).
In addition to being the template for reverse transcription, the pgRNA is translated to 
produce both the core protein and HBV DNA polymerase. The DNA polymerase binds to a 
stem-loop structure (termed epsilon) within the 5’ portion of the pgRNA to prime viral DNA 
synthesis and initiate nucleocapsid assembly (Tavis and Ganem, 1995; Tavis and Ganem, 
1996; Wang and Seeger, 1992, 1993). The encapsidated pgRNA is then reverse transcribed 
to form the minus-strand viral DNA by viral DNA polymerase. The minus-strand serves as 
the template for the plus-strand DNA synthesis. The nucleocapsid matures as rcDNA is 
formed and can be either enveloped and secreted out of the cell as a virion particle or 
redirected into the nucleus to amplify the cccDNA pool (Tuttleman et al., 1986; Wu et al., 
1990).
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The essential steps in the biosynthesis of cccDNA from the incoming virion or from the 
progeny cytoplasmic nucleocapsid rcDNA include rcDNA uncoating (nucleocapsid 
disassembly), nuclear transportation and conversion into cccDNA. The molecular 
mechanisms involved in rcDNA uncoating have been investigated by different approaches. 
Studies from Kann's group demonstrated that the cytoplasmic HBV capsids can freely pass 
the nuclear pore complex (NPC) and are captured in the nuclear basket on the nuclear side 
of the NPC, through interaction with nucleoporin 153 (Nup153). However, only the capsids 
containing a mature rcDNA disassemble in the nuclear baskets and release rcDNA into the 
nucleus (Kann et al., 1999; Rabe et al., 2003; Schmitz et al., 2010). On the other hand, 
results from our studies on the production and function of deproteinized rcDNA support a 
model that the completion of plus-strand DNA synthesis triggers the removal of viral DNA 
polymerase covalently linked to the 5’-end of minus-strand DNA. Plus-strand DNA 
synthesis also triggers a structural change in nucleocapsids in the cytoplasm, which leads to 
the translocation of the carboxyl termini of core protein to the exterior of the capsids.
Exposure of the nuclear localization signal (NLS) located at the carboxyl terminus of the 
core protein allows the matured capsids to interact with host karyopherins and import the 
deproteinized rcDNA into the nuclei for cccDNA formation. In this regard, the 
deproteinized rcDNA is a functional precursor of cccDNA (Fig. 1) (Guo et al., 2007; Guo et 
al., 2010). In agreement with the notion that maturation of nucleocapsids triggers their 
structural change or partial disassembly, biochemical and biophysical analyses of 
cytoplasmic nucleocapsids by another group revealed that the maturation of rcDNA was 
associated with nucleocapsid destabilization, as indicated by increased protease and nuclease 
sensitivity, altered sedimentation during sucrose gradient centrifugation, and slower mobility 
in native agarose gel electrophoresis (Cui et al., 2013).
Biochemically, conversion of rcDNA to cccDNA requires the removal of the polymerase 
protein and RNA primers from the 5’-terminus of minus-strand and plus-strand DNA, 
respectively, as well as trimming the DNA ends, filling in the gaps and ligation of both 
strand of DNA. Although it is speculated that all those reactions are most probably catalyzed 
by host cellular DNA repair machinery, the exact DNA repair proteins involved in those 
reactions remain to be identified. Tyrosyl-DNA phosphodiesterase-2 (Tdp2) was recently 
identified as the enzyme responsible for cleavage of tyrosyl-5′ DNA linkages formed 
between topoisomerase II and cellular DNA (Cortes Ledesma et al., 2009). Tdp-2 also 
specifically cleaves a unique protein-RNA covalent linkage generated for priming the viral 
genomic RNA replication during a picornavirus infection (Virgen-Slane et al., 2012). Since 
the hepadnaviral DNA polymerase-DNA linkage is also a 5′ DNA-phosphotyrosyl bond, it 
is plausible that Tdp2 might be responsible for the removal of DNA-linked viral polymerase 
and essential for cccDNA synthesis. However, although two independent studies 
convincingly demonstrated that Tdp2 is indeed able to cleave the tyrosyl-minus strand DNA 
linkage, using authentic rcDNA isolated from nucleocapsids as substrate, in vitro, the role of 
this enzyme in hepadnaviral cccDNA formation in virus-replicating cells remains 
controversial (Cui et al., 2015b; Koniger et al., 2014). Our studies do not favor a role of 
Tdp2 in HBV cccDNA formation either, as stably knocking down of Tdp2 in an inducible 
HBV stable cell line upregulated transgene-based viral RNA transcription and subsequent 
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DNA replication, and the levels of deproteinzed rcDNA and cccDNA were also 
proportionally increased (D. Cai and H. Guo, unpublished data).
While it is generally believed that multiple DNA repair proteins/pathways recognize the two 
gaps in rcDNA as DNA breaks and directly repair the rcDNA into cccDNA (Guo et al., 
2012; Sohn et al., 2009), it is also postulated that rcDNA may first be converted into a 
double-stranded linear DNA containing terminal repeats (TR-dsl DNA) through extension of 
both plus- and minus- strands over the cohesive end region by viral or host DNA 
polymerases, and cccDNA is subsequently formed via intra-molecular homologous 
recombination of the TR-dsl DNA (Yang et al., 1996). Although the episomal TR-dsl DNA 
has not been detected in virally- infected hepatocytes by conventional hybridization 
methods, sequence analysis of cccDNA recombinant joints and virus-host DNA junctions in 
the livers of DHBV-infected ducks and WHV-infected woodchucks suggested that the 
putative TR-dsl DNA did exist and could be converted into cccDNA and integrated into host 
chromosome by nonhomologous end joining (NHEJ) DNA repair pathway (Bill and 
Summers, 2004; Yang et al., 1996; Yang and Summers, 1995, 1999).
It is also worth noting that in addition to rcDNA, approximately 5 to 10% of hepadnaviral 
genomic DNA is double-stranded linear (dsl) DNA (Staprans et al., 1991). HBV plus-strand 
DNA synthesis in the cytoplasmic nucleocapsids is primed by a RNA oligomer derived from 
the 5’ terminal 17-18 ribonucleotides of pgRNA, which is translocated from the 3’ end of 
minus- strand DNA to pair with the DR2 sequence near the 5’ end of minus strand DNA to 
initiate plus-strand synthesis (Lien et al., 1986). The subsequent template switch circularizes 
viral DNA to yield a rcDNA (Liu et al., 2003). However, occasional failure of primer 
translocation results in in situ priming of plus-strand DNA synthesis at the 3’ end of minus-
strand DNA to produce a dslDNA (Staprans et al., 1991). The dslDNA and TR-dslDNA 
have been shown to be the direct precursors of integrated HBV in host cellular chromosome 
(Bill and Summers, 2004; Yang and Summers, 1999).
Interestingly, a recent clinical study suggested that serum dslDNA proportions progressively 
increase during the development of HBV-related liver diseases. The dslDNA proportion can 
be regulated by inflammatory cytokines, suggesting an association between inflammation, 
increased production of HBV dslDNA and development of HCC (Zhao et al., 2015). It has 
been previously shown that cccDNA can be formed from both rcDNA and dslDNA in 
hepadnavirus-infected cells (Tuttleman et al., 1986; Yang and Summers, 1995). However, 
while rcDNA is faithfully repaired to form wild-type cccDNA, the cccDNA derived from 
dslDNA carries deletions or insertions around the site of end-joining (Yang and Summers, 
1995). These observations suggest that rcDNA and dslDNA are converted into cccDNA via 
different DNA repair pathways. Indeed, using a panel of skin fibroblast and CHO cell-
derived lines deficient in specific DNA repair genes, we demonstrated that Ku80, a 
component of NHEJ DNA repair pathway, was essential for the synthesis of cccDNA from 
dslDNA, but not rcDNA (Guo et al., 2012). The advent of novel gene editing technologies 
will facilitate the systematic identification of host cellular genes required for cccDNA 
biosynthesis from rcDNA (Pyzocha et al., 2014; Zhang et al., 2014a).
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3. Regulation of cccDNA formation by viral and host factors
The copy number of cccDNA varies among individual hepatocytes and fluctuates under 
different pathobiological conditions. Studies from WHV-infected woodchucks indicated that 
the copy numbers of cccDNA in hepatocytes range from 1 to 50 (Dandri et al., 2000; Kajino 
et al., 1994). A single cell-based study revealed that in DHBV-infected ducks, cccDNA copy 
number differed significantly from cell to cell and at different time points post-infection. 
While 90% of hepatocytes contained 1 to 17 copies of cccDNA, the remaining 10% 
contained more copies (Zhang et al., 2003). Clinical studies showed that the median level of 
intrahepatic cccDNA in chronic hepatitis B patients was 1.05 copies per cell, ranging from 
0.035 to 195 copies per cell; and the levels of cccDNA decreased after HBeAg 
seroconversion (Laras et al., 2006; Wursthorn et al., 2006).
Although superinfection exclusion has not been firmly excluded for HBV-infected 
hepatocytes, the numbers of cccDNA in a virus-infected hepatocyte is presumably 
controlled by the efficiency of the intracellular cccDNA amplification pathway. For many 
animal viruses, genome uncoating strictly relies on extracellular virion phase, because the 
nucleocapsids of these viruses become mature only during the budding and secretion process 
(Ganser-Pornillos et al., 2008; Mettenleiter et al., 2009), or require interaction with viral 
receptors or an acid bath in endosomes during entry into host cells to trigger disassembly 
(Alain et al., 2007; Day et al., 2003; Smith et al., 2008). The uncoating of progeny 
nuclocapsids in infected cells is a unique feature of hepadnaviruses (Tuttleman et al., 1986; 
Wu et al., 1990). Considering that the large amounts of viral rcDNA, the precursor of 
cccDNA formation, exist in the cytoplasm and relatively small numbers of cccDNA 
accumulate in the nucleus, mature nucleocapsid uncoating and cccDNA formation must be 
tightly controlled by host and/or viral factors. In addition, because untimely uncoating and 
release of viral DNA in the cytoplasm may result in recognition of HBV infection by host 
cellular innate immune sensors to induce an antiviral response (Rasaiyaah et al., 2013), 
deliberating control of HBV genome uncoating is not only important for cccDNA formation, 
but also critical for the virus to evade host restriction (Le Sage et al., 2014).
A series of elegant studies by Summers and colleagues suggested that the DHBV large 
envelope protein regulated intracellular HBV DNA traffic and cccDNA formation (Lenhoff 
and Summers, 1994; Summers et al., 1990). When the level of large envelope protein is low 
in the early phase of infection, nuclear delivery of mature nucleocapsid is favored, which 
allows rapid establishment of the cccDNA pool and ensures that infected cells will be stably 
colonized. When cccDNA is amplified to reach a level that supports the synthesis of 
sufficient amount of large envelope proteins for virion assembly, the mature nucleocapsids 
will be primarily enveloped and secreted as virions. The tight control of DHBV cccDNA 
amplification by large envelope protein is demonstrated in primary duck hepatocytes and 
DHBV-infected ducks in vivo. For instance, infection of envelope protein-deficient 
recombinant DHBV results in approximately 20-fold more cccDNA accumulation and 
ultimately death of the infected hepatocytes (Lenhoff et al., 1999; Summers et al., 1990; 
Summers et al., 1991). However, investigations in human hepatoma cells demonstrated that 
the deficiency of HBV envelope proteins increased the level of cccDNA by only two-fold, 
but resulted in a dramatic accumulation of the deproteinized rcDNA (Gao and Hu, 2007; 
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Guo et al., 2007; Lentz and Loeb, 2011). The modest impact of HBV envelope proteins on 
cccDNA amplification suggests that other viral and host cellular factors regulate HBV 
cccDNA synthesis. Identification of the viral and host factors that determine the set points of 
cccDNA in HBV-infected hepatocytes may provide therapeutic targets for elimination of 
cccDNA.
DHBV cccDNA can be efficiently accumulated in many different types of human and 
animal cells (Guo et al., 2012), but formation of HBV cccDNA has only been consistently 
observed in infected human hepatocytes and selected human hepatoma cell lines. 
Particularly, HBV fails to synthesize cccDNA in the hepatocytes of HBV transgenic mice, 
despite the existence of large amount of rcDNA-containing nucleocapsids (Guidotti et al., 
1995). Moreover, transgenic expression of human sodium taurocholate cotransporting 
polypeptide (NTCP) in mouse hepatocytes, the bona fide receptor of HBV and its satellite 
hepatitis D virus (HDV) (Yan et al., 2012), confers HDV infection susceptibility to mouse 
hepatocytes, but not HBV-infection susceptibility (He et al., 2015). This finding suggests 
that besides the lack of a functional receptor, failure to support efficient cccDNA formation 
might also account for the nonsusceptibility of mouse hepatocytes to HBV infection. 
Interestingly, trace amount of cccDNA can be detected in the livers of HNF-1α-null HBV 
transgenic mice, suggesting that host factors regulate cccDNA formation and/or 
accumulation in mouse hepatocytes (Raney et al., 2001).
It was reported recently by Cui and colleagues that HBV cccDNA could be detected in a 
TGF-α-immortalized mouse hepatocyte cell line AML12HBV10, and that AML12HBV10 
cells support a tetracycline-inducible HBV replication (Xu et al., 2010), where mature 
nucleocapsids are not stable and rcDNA are efficiently uncoated for cccDNA formation (Cui 
et al., 2015a). This work thus suggests that disassembly of mature nucleocapsids is subject 
to host cellular regulation and could thus be one of the critical determinants of host range 
and/or cell tropism of HBV. Further investigation into the molecular mechanism regulating 
cccDNA formation in mouse hepatocytes could establish intellectual basis for the 
development of mouse models supporting efficient HBV infection.
4. Structure and function of cccDNA minichromosome
Like other nuclear viral episomal DNA, hepadnaviral cccDNA molecules in the nuclei of 
infected cells associate with nucleosomes and assemble into host cellular chromatin-like 
structures, designated as minichromosomes (Bock et al., 1994; Newbold et al., 1995). 
Mapping the distribution of nucleosomes along DHBV cccDNA in the livers of infected 
ducks showed that nucleosomes are not randomly positioned on cccDNA. Particularly, 
several nucleosome-protected sites in the region of the DHBV genome [nucleotides (nt) 
2000 to 2700], known to harbor various cis transcription regulatory elements, were 
consistently identified in all DHBV-infected livers. These observations suggest that, like 
host cellular chromatin, nucleosome positioning and histone modification of the 
minichromosomes may play an important role in regulation of cccDNA transcription (Shi et 
al., 2012). Indeed, HBV replication activity in the liver of patients correlated with the 
acetylation status of HBV cccDNA-bound H3 and H4 histones (Pollicino et al., 2006). We 
also found that certain histone deacetylase (HDAC) inhibitors potently inhibited DHBV and 
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HBV cccDNA transcription, and IFN-α suppressed DHBV cccDNA transcription by 
reducing the acetylation of cccDNA-associated histone H3 lysine 9 (H3K9) and 27 (H3K27) 
(Liu et al., 2013).
In addition to nucleosomes, host cellular transcription factors, co-activators, corepressors, 
chromatin-modifying enzymes, as well as viral proteins, such as core and HBx proteins, 
have also been demonstrated to be recruited to cccDNA minichromoses under certain 
conditions to regulate cccDNA transcription activity (Levrero et al., 2009; Nassal, 2015). 
WHV X protein has been shown to be essential for the virus to establish infection in vivo 
(Zoulim et al., 1994). Infection of primary human hepatocyte and differentiated HepaRG 
cultures with HBV virions containing genomes-deficient in HBx expression resulted in 
equal amounts of cccDNA formation as in cells infected with HBV virions containing wild-
type genomes. However, HBV RNA was only detectable in cells infected with wild-type 
HBV virions (Lucifora et al., 2011; Riviere et al., 2015). Interestingly, trans-
complementation of HBx was able to rescue HBV mRNA transcription in cells infected with 
HBx-deficient virions, even weeks after initial infection (Lucifora et al., 2011). Further 
epigenetic analyses indicated that HBx was recruited to the cccDNA minichromosomes and 
modulated histone modifications, which promoted histone acetylation of cccDNA 
minichromosome and thus favored the establishment of a transcriptionally active chromatin 
structure (Belloni et al., 2009). In addition, HBx was also demonstrated to enhance cccDNA 
transcription by counteracting the activity of transcriptional repressor(s) that silence the 
virus transcription. For instance, it was reported recently that Spindlin1, a cellular Tudor-
domain protein, was more efficiently recruited to HBV cccDNA in the absence of HBx and 
suppressed the transcription activity of cccDNA. Silencing of Spindlin1 expression restored 
cccDNA transcription in the absence of HBx expression, which correlated with increased 
H3K4me3 at cccDNA minichromosomes. On the contrary, expression of HBx reduced 
Spindlin1 recruitment to cccDNA and activated its transcription activity (Ducroux et al., 
2014). Moreover, a recent study also showed that HBx protein helped overcome SETDB1-
mediated H3K9me3 and HP1 induced condensation of cccDNA minichromosomes to 
activate cccDNA transcription (Riviere et al., 2015).
Several lines of evidence from independent research groups have suggested that HBV capsid 
protein (HBcAg) is also associated with cccDNA minichromosomes (Bock et al., 2001; Guo 
et al., 2011; Lucifora et al., 2014). Interestingly, it was reported that the primary duck 
hepatocytes infected with DHBV containing genomes deficient in capsid protein expression 
accumulated similar amounts of cccDNA, but significantly less amounts of viral mRNA, 
compared to the cells infected with wild-type DHBV in the presence of foscarnet to block 
viral DNA replication and intracellular amplification of cccDNA (Schultz et al., 1999). This 
finding suggests that DHBV capsid protein may regulate cccDNA transcription and/or viral 
RNA turnover. However, we found that HepG2 cells transfected with either wild-type or 
capsid-deficient unit-length HBV DNA accumulated similar amounts of HBV mRNA, 
indicating that capsid protein did not regulate HBV transcription or viral mRNA turnover 
under our experimental conditions (Zhang et al., 2014b). Thus, the possible role of HBV 
capsid protein in cccDNA metabolism and function awaits further investigation in more 
biologically relevant systems.
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HBV cccDNA contains three major CpG islands that can potentially be methylated (Zhang 
et al., 2013). Accumulating evidence suggests that variable degrees of CpG methylation 
were present in cccDNA from patients with chronic HBV infection. Old age and low viral 
loads were significantly associated with elevated cccDNA methylation (Kim et al., 2011). 
Our recent profiling of cccDNA methylation in chronic HBV infected patients revealed that 
while CpG island I was rarely methylated, methylation of CpG islands II and III was 
associated with low viral loads. Moreover, cell-based assays also demonstrated that CpG 
island II methylation significantly reduced the transcriptional activity of cccDNA (Zhang et 
al., 2014b).
Obviously, the minichromosomal structure and epigenetic modifications critically regulate 
the maintenance and transcriptional activity of cccDNA. Further understanding the 
epigenetic regulation and its relationship with cccDNA stability and function may reveal 
molecular targets for development of therapeutic agents to destabilize cccDNA or 
specifically silence its transcription.
5. Metabolism of cccDNA and mechanism of the cure of infected 
hepatocytes
Unlike the covalently closed circular form of nuclear episomal DNA from other DNA 
viruses, such as polyomaviruses, papillomaviruses and γ-herpesviruses, that can 
semiconservatively replicate in the nuclei of host cells, HBV cccDNA cannot replicate itself, 
but can only be made from cytoplasmic capsid DNA (Wu et al., 1990). Maintenance of 
cccDNA in a persistently infected hepatocyte thus relies on the intricate stability of cccDNA 
minichromosmes and/or the efficient replenishment of cccDNA through intracellular 
amplification pathway. If the turnover of cccDNA molecules does occur in infected 
hepatocytes, complete inhibition of viral DNA replication with antiviral agents inhibiting 
any step of viral DNA replication should ultimately deplete the precursors of cccDNA and 
consequentially, eradicate cccDNA. Accordingly, answers to the following three related 
questions are critical to understand the metabolism of cccDNA and mechanism of the cure 
of infected hepatocytes: (i) How stable are cccDNA minichromosomes in non-dividing 
cells? (ii) Could cccDNA molecules survive cell division? (iii) How are cccDNA molecules 
cleared during the resolution of HBV infections?
5.1 Longevity of cccDNA
Many attempts have been made to determine the half-life of HBV and other hepadnavirus 
cccDNA under various conditions. It has been shown that WHV cccDNA is stably 
maintained for months in non-dividing primary woodchuck hepatocytes (Moraleda et al., 
1997). HBV cccDNA in confluent HepG2-derived cell lines, such as HepAD38 and 
HepDES19 cells, is also apparently very stable (Cai et al., 2012; Zhou et al., 2006). These 
observations corroborate the long half-life of hepadnavirus cccDNA, observed in HBV-
infected chimpanzees (Wieland et al., 2004), WHV-infected woodchucks (Zhu et al., 2001) 
and DHBV-infected ducks (Addison et al., 2002) receiving viral polymerase inhibitor 
therapies, which were 9-14, 33-50 and 35-57 days, respectively. Nevertheless, in all those 
experimental conditions, it is difficult to conclude whether the observed cccDNA turnover is 
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due to the decay of cccDNA in living cells, loss and/or dilution of cccDNA during cell 
division, or death of infected cells.
5.2 Fate of cccDNA during cell division
HBV is not a cytopathic virus, and infected cells continue to grow and divide (Chisari and 
Ferrari, 1995). Even though hepatocytes may divide only once in half a year in the normal 
liver (MacDonald, 1961; Magami et al., 2002), the proliferation rate is greatly enhanced 
during viral infection, due to inflammation and regeneration (Guo et al., 2000). cccDNA 
minichromosomes do not have centromeres and therefore can be lost during cell division 
(Calos, 1998). However, work reported by others and us has suggested that DHBV cccDNA 
could be passed into daughter cells (Guo et al., 2003; Lutgehetmann et al., 2010; Reaiche-
Miller et al., 2013). Therefore, the open questions are: how cccDNA molecules survive 
mitosis and whether cccDNA are randomly or equally distributed into daughter cells.
The same questions apply to the nuclear episomal DNA of other viruses. In fact, 
papillomaviruses and γ-herpesviruses do establish latent infections as episomes in the nuclei 
of dividing cells. These viruses attach their episomal genomes to mitotic cellular 
chromosomes non-covalently via a viral protein for effective preservation and partitioning 
during cell division (Ballestas et al., 1999; Hung et al., 2001; Lehman and Botchan, 1998; 
You et al., 2004; You et al., 2006). So far, it is not known if hepadnavirus cccDNA is 
distributed into progeny cells via a similar mechanism, but obviously, disruption of cccDNA 
partitioning into daughter cells should be an effective way to accelerate the decay of 
cccDNA.
5.3 Non-cytolytic cure of HBV-infected hepatocytes
In regard to the mechanism of resolution of acute HBV infection, one possibility is that all 
the infected hepatocytes are killed during the recovery phase and replaced by the 
proliferation of uninfected hepatocytes. However, studies in WHV-infected woodchucks, 
DHBV-infected ducks and HBV-infected chimpanzees demonstrated that at the peak of 
transient infection, almost 100% of hepatocytes were infected (Guidotti et al., 1999; Jilbert 
et al., 1992; Kajino et al., 1994). Despite the fact that killing of hepatocytes does occur in 
the recovery phase, the total amount of hepatocyte death and turnover are significantly less 
than required for resolution of the infection under the condition that cccDNA are partitioned 
into daughter cells during cell division and every cccDNA-containing hepatocytes are killed 
(Guidotti et al., 1999; Wieland et al., 2004). Instead, experimental data support the 
hypothesis that during the clearing phase of HBV infection, host immune responses non-
cytopathically inhibit viral replication and greatly shorten the half-life of cccDNA, thereby 
limiting the extent to which cytopathic T-cell effector functions and tissue destruction are 
required to terminate the infection (Murray et al., 2005).
Intriguingly, using integrated viral DNA as a genetic marker of virally infected hepatocytes, 
Summers and colleagues demonstrated that the integrated viral DNA persist in liver tissues 
from recovered animals at essentially undiminished levels of 1 viral genome per 1,000-3,000 
liver cells (Summers et al., 2003). This finding unambiguously supports the notion that the 
hepatocytes in the recovered liver were derived primarily from the infected cell population 
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and non-cytolytic eradication of cccDNA from infected hepatocytes does occur during the 
resolution of HBV infection. One of the possible mechanisms to eradicate cccDNA from 
hepatocytes is that cytokine-induced antiviral responses either lead to the degradation of 
cccDNA or accelerate the loss of cccDNA during cell division. The latter hypothesis 
predicts that the clearance of cccDNA requires infected hepatocytes to divide at least once 
during the recovery phase.
Interestingly, it was reported recently that the treatment of HBV-infected human primary 
hepatocytes or HepaRG cells with IFN-α or a lymphotoxin-β receptor (LTβR) agonist 
induced the expression of cytidine deaminase APOBEC3A and 3B, which were 
subsequently recruited to cccDNA minichromosomes by HBV core protein to edit cccDNA 
on the plus strand. Deaminated cccDNA was subjected to DNA repair and was ultimately 
degraded via a mechanism involving apurinic/apyrimidinic (AP) endonuclease (APE-1), 
(Lucifora et al., 2014). It is thus of interest to know whether IFN-α induces cccDNA decay 
via a similar mechanism in human hepatocytes, in vivo, and why IFN-α therapy only cures a 
small fraction of treated patients (Chisari et al., 2014; Shlomai and Rice, 2014).
Taken together, it appears that cccDNA is stable, but can be degradated by innate and 
adaptive immune response-induced intracellular antiviral programs in stationary cells. Like 
many other viral episomal DNAs, cccDNA can also be partitioned into daughter cells during 
cell division. Theoretically, cccDNA-free hepatocytes can be produced by single or multiple 
rounds of cell division due to unequal distribution and/or dilution of cccDNA. Nevertheless, 
our recent studies indicate that IFN-α does not significantly accelerate DHBV cccDNA loss 
during cell division (F. Liu and J.-T. Guo, unpublished observations).
6. Therapeutic elimination or silencing of cccDNA
6.1 Sequence-specific cleavage of cccDNA
Selective elimination of cccDNA relies on targeting its unique molecular features. 
Obviously, the most distinct molecular feature of cccDNA that differentiates it from host 
cellular chromatin is its unique DNA sequence. Therefore, several sequence-specific DNA 
targeting technologies, such as zinc finger proteins (Hoeksema and Tyrrell, 2010; Weber et 
al., 2014; Zimmerman et al., 2008), transcription activator-like effector nuclease (TALENs) 
(Bloom et al., 2013; Chen et al., 2014), and the clustered regularly interspaced short 
palindromic repeats (CRISPR)/CAS9 (Dong et al., 2015; Lin et al., 2014; Liu et al., 2015; 
Ramanan et al., 2015; Ren et al., 2015; Seeger and Sohn, 2014), have been evaluated in 
cultured cells and in mouse models. These approaches have demonstrated specific cleavage 
of cccDNA or inhibition of cccDNA transcription.
It is particularly interesting that CRISPR/CAS9 with different HBV-specific guide RNAs 
can be efficiently recruited to cccDNA minichromosomes, formed in HBV-infected, NTCP-
expressing HepG2 cells, to induce mutations and deletions in cccDNA similar to those 
observed with chromosomal DNA cleaved by Cas9 and repaired by NHEJ pathway (Seeger 
and Sohn, 2014). However, efficient delivery of these gene-editing molecules into all HBV-
infected cells in vivo is a major challenge for their clinical application.
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6.2 Potential therapeutic targets for elimination or silencing of cccDNA
Recent findings about the immunological control of cccDNA by interferons and 
lymphotoxin raise exciting possibilities to target cccDNA via pharmacological activation or 
augmentation of the host intrinsic antiviral pathways (Liu et al., 2013; Lucifora et al., 2014). 
In addition, investigation of the mechanisms of HBx and core protein in cccDNA 
metabolism and function may reveal viral-host interactions for selective elimination or 
silencing of cccDNA (Lucifora et al., 2011; Riviere et al., 2015).
It is generally claimed that failure to eliminate cccDNA underlines the inability of current 
therapeutics to cure HBV infection, but the persistence of cccDNA can occasionally be 
detected in the livers of individuals with resolved HBV infections, and HBV replication can 
be reactivated in these individuals while suffering from systemic immune suppression or 
receiving anti-cancer chemotherapy (Pattullo, 2015; Rehermann et al., 1996). These 
observations indicate that the restoration of a functional antiviral immune response against 
HBV, but not necessarily the sterilized clearance of HBV cccDNA, might be more important 
for achieving a functional cure for HBV infection. Investigation to understand how immune 
system purges cccDNA and keeps the residual HBV (cccDNA) under surveillance will shed 
light into the development of immunotherapeutics to durably control HBV infection. In 
particular, reactivation of occult or immune-controlled HBV infection by anti-TNF-α 
therapy suggests that the cytokine plays a critical role in immune surveillance of HBV 
infection (Cassano et al., 2011).
It will be interesting to know if the immune system controls residual HBV replication by 
suppressing cccDNA transcription or via posttranscriptional mechanisms.
As we learned from studying the mechanism of IFN-α suppression of DHBV cccDNA 
transcription in cultured cells, IFN-α or possibly other cytokines may induce epigenetic 
remodeling of cccDNA minichromosome to induce a prolonged suppression of its 
transcription (Liu et al., 2013). It can thus be speculated that the immune surveillance of 
residual HBV replication may work through cytokine-induced transcriptional silencing of 
cccDNA function. Pharmacological activation of such intracellular responses in virus-
infected cells might be able to durably control HBV replication.
6.3 Discovery of cccDNA-targeting antivirals through phenotypic screening
Despite being a reasonable approach, screening for anti-cccDNA agents has not been 
vigorously conducted, due to the lack of efficient in vitro infection models and a practical 
approach to measure cccDNA in medium- to high-throughput formats. Although there are 
primary human hepatocytes (PHH), HepaRG cells, and the recently established HepG2-
NTCP cell culture systems available to support cccDNA-dependent HBV replication, the 
efficiency of HBV infection in vitro remains low, even with large virus inocula (Gripon et 
al., 2002; Iwamoto et al., 2014; Ni et al., 2014; Schulze-Bergkamen et al., 2003; Seeger and 
Sohn, 2014; Yan et al., 2014). In addition, there is a high degree of variability of HBV 
infectivity in primary hepatocytes from donor to donor, with some batches proving to be 
uninfectable, and the HepaRG system requires much manipulation for experimental setup 
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(Gripon et al., 2002). These characteristics restrict their utility for screening compound 
libraries.
Alternatively, cccDNA formation can be achieved through the intracellular amplification 
pathway in stably-transfected HBV cell cultures that constitutively or conditionally replicate 
HBV genome (Chou et al., 2005; Guo et al., 2007; Ladner et al., 1997; Sells et al., 1988), as 
represented by HepG2.2.15 line (Schmidt and Korba, 2000; Sells et al., 1987). However, the 
direct detection of cccDNA from HBV cell lines by either Southern blot hybridization or 
real-time PCR assays would not be amenable to high throughput screening due to their 
limited sensitivity and specificity, respectively. On the other hand, there is no suitable 
surrogate marker for cccDNA in HepG2.2.15 cells since the majority of viral products are 
derived from integrated viral transgene, which is indistinguishable from cccDNA 
contributions.
To surmount this obstacle, we previously established a HepDE19 stable cell line that 
expresses HBeAg in a cccDNA-dependent manner (Fig. 2). HBeAg is a secreted viral 
protein dispensable for HBV DNA replication and cccDNA formation. The strategy is based 
on the principle that the HBV cccDNA can be made from a pgRNA transcript alone, along 
with its translation products (core and pol) via the intracellular amplification pathway. The 
ORF of HBeAg is divided between the two termini of pgRNA and is only reconstituted 
when the pgRNA is reverse transcribed and circularized into cccDNA. HepDE19 cells 
contain an integrated HBV genome spanning the entire viral pgRNA and precore mRNA 
region under the control of a tetracycline-regulated (tet-off) CMV-IE promoter. A point 
mutation of the precore start codon at the 5’ end of the transgene was introduced to prevent 
expression of precore from the transgene. Upon induction, the transcribed pgRNA expresses 
viral core protein and polymerase and initiates reverse transcription of pgRNA to generate 
rcDNA, resulting in cccDNA formation. Meanwhile, the start codon of the precore open 
reading frame (ORF) at the 3’ end of pgRNA is copied into a viral DNA sequence, and the 
ORF of precore is restored during rcDNA conversion into cccDNA. Thus, authentic precore 
mRNA can be transcribed only from cccDNA. The precore protein product is further 
processed and secreted as HBeAg, which serves as a surrogate marker for cccDNA and can 
be conveniently detected by ELISA. HepDE19 cell line provided the first cccDNA reporter 
system for screening inhibitors targeting HBV cccDNA establishment or maintenance. By 
making use of the HepDE19 system, we previously screened a small-molecule compound 
library and identified two disubstituted sulfonamide (DSS) compounds that act as inhibitors 
of cccDNA formation by blocking rcDNA deproteinization. DSS compounds serve as proof-
of-concept drug candidates for development into therapeutics, to eliminate cccDNA from 
chronically HBV infected patients. (Cai et al., 2012).
However, the existing assay is not ideal for high-throughput screening, because the HBeAg 
ELISA cross-reacts with an HBeAg homologue, the core antigen (HBcAg). HBcAg is an 
abundant, secreted protein, produced largely from the transgene template in HepDE19 cells 
(Guo et al., 2007). The HBeAg shares 149 amino acid (aa) sequence homology with HBcAg 
(Block et al., 2007), and a highly specific HBeAb or HBeAg ELISA is not available, 
resulting in a low HBeAg signal-to-noise ratio (tet- vs. tet-/3TC) in HepDE19 cell-based 
assay. To further improve the specificity and sensitivity of the assay, we have embarked 
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upon generating the “second-generation” cccDNA reporter cell systems by incorporating an 
epitope tag in the precore region or replacing the precore ORF with a luminescent or 
colorimetric reporter gene. We have recently established a new HBV cell line expressing 
human influenza hemagglutinin (HA) epitope-tagged HBeAg in cccDNA-dependent 
manner. The HA-HBeAg ELISA assay with HA antibody serving as the capture antibody 
and anti-HBe antibody serving as detection antibody, completely eliminated the 
contaminating signal from HBcAg (D. Cai and H. Guo, unpublished data). The novel 
reporter systems provide powerful tools for phenotypic screening of cccDNA-targeting 
antiviral substances, as well as host factors that regulate cccDNA metabolism and function.
7. Conclusions and perspectives
Our knowledge of cccDNA biosynthesis, transcription regulation and turnover in HBV-
infected hepatocytes is incomplete, and we have no therapeutic means to reliably control 
cccDNA. Future investigation towards
(i) understanding the molecular pathway of cccDNA formation,
(ii) knowing how cccDNA survives cell division,
(iii) revealing the mechanism of immunologic elimination and silencing of cccDNA 
and
(iv) understanding how HBx and core protein control cccDNA transcription
should not only advance our knowledge of hepatitis B pathobiology, but also provide clues 
or validate targets for the development of therapeutics to eradicate or suppress cccDNA. 
Further development and optimization of cccDNA-reporter cells and NTCP-based HBV 
infection systems should greatly improve our ability to investigate cccDNA metabolism and 
functional regulation, as well as the discovery of drug candidates for durable control of HBV 
infection.
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Highlights
• Hepatitis B virus (HBV) persistence relies on the stable maintenance and proper 
functioning of cccDNA.
• cccDNA is synthesized from viral genomic DNA of the infecting virion or from 
the progeny mature nucleocapsid.
• Copy numbers of cccDNA in the nuclei of infected hepatocytes are controlled 
by both viral and host cellular factors.
• Eradication or transcriptional silencing of cccDNA is essential for a cure of 
HBV infection.
• High-throughput cccDNA quantification and functional assays are needed for 
discovery of cccDNA-targeting antivirals.
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Fig 1. Proposed model for the molecular pathway of HBV cccDNA formation
In the cytoplasm, completion of viral plus-strand DNA synthesis inside the nucleocapsid 
triggers the removal of the viral polymerase from minus-strand DNA. This deproteinization 
reaction is associated with a nucleocapsid conformational change (“uncoating” step 1), 
resulting in exposure of the nuclear localization signal (NLS) at the C-terminus of the capsid 
protein on the nucleocapsid surface, followed by binding of cellular karyopherins and 
nuclear import of the DP-rcDNA-containing capsid. In the nucleus, DP-rcDNA is released 
from the capsid (“uncoating” step 2) and converted into cccDNA by employing the host 
DNA repair machinery.
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Fig 2. HBV nucleic acid metabolism in HepDE19 cells, with the rationale for design of a cccDNA-
dependent HBeAg assay.
(A) The transgene in HepDE19 cells contains a 1.1 overlength HBV genome (genotype D, 
subtype ayw), starting from nt 1805, under the control of a tet-CMV promoter (tet-off), in 
which the start codon (AUG) of the precore (pC) ORF has been mutated to UG at the 5’ end 
of HBV DNA, with the second one at the 3’ redundancy (r’) left unchanged. C, pol, pS1, 
pS2, S and X represent ORF for core, polymerase, preS1, preS2 and S domain of HBV 
surface antigen, and X protein, respectively. DR represents the identical direct repeat 
sequences 1 and 2. pA is polyadenylation site. (B) Upon tetracycline withdrawal, HBV 
pgRNA is transcribed and the viral core and polymerase are produced, resulting in pgRNA 
encapsidation, (C) reverse transcription of pgRNA to minus-strand DNA, and (D) sequential 
plus-strand DNA synthesis and circularization into rcDNA. (E) rcDNA is converted to the 
cccDNA template, in which the precore ORF is restored, giving rise to authentic precore 
mRNA, and (F) pgRNA. (G) cccDNA-derived precore mRNA is translated into the precore 
protein, which is further processed into secreted HBeAg through proteolytic cleavage of the 
N-terminal signal peptide and C-terminal domain (CTD). The secreted HBeAg in the 
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supernatant of HepDE19 cells can be detected by ELISA assay and serves as a surrogate 
marker for intracellular cccDNA.
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